Table 4.

Summary of recent reports of outcome using metallic stents. The 3-, 6-, and 12-month patency rates were 77–88%, 51–67%, and 20–41%, respectively.

Investigators	Year	n	Study design	Stent type	AVF or AVG	Primary patency (%)			(months)
						3 M	6 M	12 M
Vogel and Parise [12]	2004	53	Retrospective	SMART	AVG	77 (61–93)	51 (34–67)	20 (12–27)	mean 8.9
Vogel and Parise [14]	2005	25	Prospective, Non-randomized	SMART	AVG	88 (75–100)	67 (48–86)	41 (21–61)	mean 8.2
Pan et al. [21]	2005	12	Retrospective	Wallstent, Jostent	AVF	92 ± 8	81 ± 12	31 ± 17	n/a
Liang et al. [22]	2006	23	Observational	Wallstent, nitinol	AVG	69 ± 9	41 ± 10	30 ± 10	n/a
Maya and Allon [23]	2006	14	Prospective, Non-randomized	Wallstent, SMART, Protégé, Fluency	AVG	48	19	n/a	median 2.8
Chan, M.R. et al. [24]	2008	211	Retrospective	SMART	AVG	69	25	n/a	median 4.4
Current study	2011	50	Prospective, Observational	SMART	Both	79 ± 9	51 ± 15	27 ± 16	median 3.8
		25			AVF	80 ± 10	65 ± 16	32 ± 21	median 5.2
		25			AVG	76 ± 15	28 ± 22	19 ± 17	median 2.9